OTCMKTS:SIGY Sigyn Therapeutics Q4 2024 Earnings Report $0.03 0.00 (0.00%) As of 09/25/2026 ProfileEarnings History Sigyn Therapeutics EPS ResultsActual EPS-$2.51Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASigyn Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASigyn Therapeutics Announcement DetailsQuarterQ4 2024Date4/15/2025TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsSigyn Therapeutics' next earnings date is estimated for Wednesday, November 18, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Sigyn Therapeutics Earnings HeadlinesSIGY Sigyn Therapeutics Inc.May 20, 2026 | seekingalpha.comSigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTEApril 2, 2026 | finance.yahoo.comIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed forces. One writer says the request echoes a secret January meeting outside Washington, D.C., where an anonymous source described American military protection as part of something much bigger, involving Trump, Iran, and potentially trillions of dollars.September 26 at 1:00 AM | Banyan Hill Publishing (Ad)Sigyn Therapeutics Delays Annual SEC FilingMarch 31, 2026 | tipranks.comScientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory DiseasesMarch 24, 2026 | finance.yahoo.comSigyn Therapeutics Issues Shareholder Update Regarding Potential Merger and Asset Sale InitiativesMarch 13, 2026 | finance.yahoo.comSee More Sigyn Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sigyn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sigyn Therapeutics and other key companies, straight to your email. Email Address About Sigyn TherapeuticsSigyn Therapeutics (OTCMKTS:SIGY) is a biotechnology company developing therapeutic technologies for life-threatening conditions involving excessive inflammation and circulating pathogens. Its lead product candidate, Sigyn Therapy, is an investigational blood-purification device designed to remove inflammatory cytokines and pathogen-associated toxins from a patient’s blood. The company is evaluating Sigyn Therapy for potential use in conditions such as cytokine storm and endotoxemia, including inflammatory complications associated with severe infections and other diseases. The technology is intended to support the body’s immune response by reducing harmful substances in the bloodstream, but it remains under development and has not been established as an approved treatment. Sigyn Therapeutics is headquartered in the United States and focuses primarily on advancing its platform through research, development and potential clinical applications. Publicly available information about the company’s commercial operations, geographic reach and current leadership is limited.View Sigyn Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
